Axsome Therapeutics, Inc (AXSM) Debt by Year
Axsome Therapeutics, Inc carried $117.7M in long-term debt against $322.9M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 34.8% from the prior fiscal year. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Axsome Therapeutics, Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
AXSM Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY21DEF 14A | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $117.7M-34.8% | $180.7M+1.5% | $178.1M+88.9% | $94.3M+92.0% | $49.1M+1.6% | $48.3M+178.8% | $17.3M+378.9% | $3.6M-45.7% | $6.7M-29.6% | $9.5M | N/A | N/A |
| Cash & Equivalents | $322.9M+2.4% | $315.4M-18.3% | $386.2M+92.3% | $200.8M+132.3% | $86.5M-53.0% | $183.9M-16.4% | $220.0M+1474.7% | $14.0M-58.9% | $34.0M-7.1% | $36.6M-23.8% | $48.0M+1735.0% | $2.6M |
AXSM Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $118.0M+0.4% | $117.8M-35.0% | $117.7M-34.8% | $117.6M-34.6% | $117.5M-34.5% | $181.4M+1.5% | $180.7M+1.5% | $180.0M+1.4% | $179.3M+1.4% | $178.7M+21.1% | $178.1M+88.9% | $177.4M+88.9% |
| Cash & Equivalents | $319.9M+5.6% | $305.1M+1.4% | $322.9M+2.4% | $325.3M-0.6% | $303.0M-4.0% | $300.9M-9.2% | $315.4M-18.3% | $327.3M-21.4% | $315.7M-27.8% | $331.4M+34.5% | $386.2M+92.3% | $416.6M+83.1% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Axsome Therapeutics, Inc financials
Frequently Asked Questions
What was Axsome Therapeutics, Inc's long-term debt in fiscal year 2025?
Axsome Therapeutics, Inc carried $117.7M in long-term debt against $322.9M in cash and equivalents at the end of fiscal year 2025.
How fast is Axsome Therapeutics, Inc's long-term debt growing?
Axsome Therapeutics, Inc (AXSM) long-term debt fell by 34.8% year over year, from $180.7M to $117.7M in fiscal year 2025.
What was Axsome Therapeutics, Inc's long-term debt in the most recent quarter?
Axsome Therapeutics, Inc (AXSM) reported $118.0M in long-term debt in Q2 2026. This represents an increase of 0.4% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Axsome Therapeutics, Inc (AXSM) reported on that line in every period on record.